Thanks for your take on it. Animoca shouldn't have a problem getting back to me in a quick email as it's pretty straight forward should it be along the lines you've said.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%